Update on second primary malignancies in multiple myeloma: a focused review

The last decade has seen significant advances in the management of patients with multiple myeloma (MM). With increasingly effective therapies, MM patients are living longer. With improvements in survival, long-term complications including second primary malignancies are becoming new challenges in pr...

Full description

Saved in:
Bibliographic Details
Published inLeukemia Vol. 28; no. 7; pp. 1423 - 1426
Main Authors Landgren, O, Mailankody, S
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.07.2014
Nature Publishing Group
Subjects
692/420/755
692/699/67/1990/804
692/700/565/1436
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Bone marrow
Cancer Research
Care and treatment
Complications
concise-review
Critical Care Medicine
Development and progression
Hematology
Humans
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Intensive
Internal Medicine
Leukemia
Medical case management
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Multiple myeloma
Multiple Myeloma - drug therapy
Myelodysplastic syndromes
Neoplasms, Second Primary - epidemiology
Neoplasms, Second Primary - etiology
Oncology
Patients
Risk
Skin cancer
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
United States > US
Sweden
secondary malignancy
treatment
multiple myeloma
lenalidomide
acute myeloid leukemia
myelodysplastic syndromes
Online AccessGet full text

Cover

More Information
Summary:The last decade has seen significant advances in the management of patients with multiple myeloma (MM). With increasingly effective therapies, MM patients are living longer. With improvements in survival, long-term complications including second primary malignancies are becoming new challenges in providing optimal care for MM patients. Three randomized studies have demonstrated possible clinical benefit with maintenance lenalidomide for patients with MM. These same studies have also demonstrated an increased risk of second primary malignancies. In this review, we will update on the current information regarding mechanisms and risk of developing second primary malignancies with a particular focus on disease- and treatment-related factors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2014.22